▶ 調査レポート

世界の心臓バイオマーカー市場2022年-2027年:成長・動向・新型コロナの影響・市場予測

• 英文タイトル:Cardiac Biomarkers Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Mordor Intelligenceが調査・発行した産業分析レポートです。世界の心臓バイオマーカー市場2022年-2027年:成長・動向・新型コロナの影響・市場予測 / Cardiac Biomarkers Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027) / MRC2203A107資料のイメージです。• レポートコード:MRC2203A107
• 出版社/出版日:Mordor Intelligence / 2022年1月
• レポート形態:英文、PDF、100ページ
• 納品方法:Eメール(受注後2-3営業日)
• 産業分類:医療
• 販売価格(消費税別)
  Single User¥703,000 (USD4,750)▷ お問い合わせ
  Site Licence¥962,000 (USD6,500)▷ お問い合わせ
  Corporate License¥1,295,000 (USD8,750)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
Mordor Intelligence社の本市場調査レポートでは、世界の心臓バイオマーカー市場について調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、種類別(クレアチンキナーゼ、トロポニン、ミオグロビン、虚血修飾アルブミン、その他)分析、用途別(うっ血性心不全、急性冠症候群、心筋梗塞、アテローム性動脈硬化症、その他)分析、検査場所別(ポイントオブケア検査、実験室検査)分析、地域別(北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米)分析、競争状況、市場機会・将来傾向など、以下の構成でまとめました。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・市場動向
・世界の心臓バイオマーカー市場規模:種類別(クレアチンキナーゼ、トロポニン、ミオグロビン、虚血修飾アルブミン、その他)
・世界の心臓バイオマーカー市場規模:用途別(うっ血性心不全、急性冠症候群、心筋梗塞、アテローム性動脈硬化症、その他)
・世界の心臓バイオマーカー市場規模:検査場所別(ポイントオブケア検査、実験室検査)
・世界の心臓バイオマーカー市場規模:地域別(北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米)
・競争状況(Abbott Laboratories、Becton, Dickinson and Company、BioMerieux、…)
・市場機会・将来傾向

Biomarkers enable the timely identification of cardiovascular conditions and help patients prevent conditions, like myocardial infarction and acute coronary syndrome. According to WHO, around 17.9 million people died from CVDs in 2016, representing 31% of all global deaths. Myocardial infarction is one of the conditions that occur due to cardiovascular diseases. It causes significant mortality and morbidity. A timely diagnosis of heart conditions allows clinicians to analyze the risk of their patients and prescribe relevant treatment. The increasing awareness about early diagnosis using cardiovascular biomarkers among patients and healthcare providers, along with factors, like growing funding from public and private organizations for R&D and technological advancements is expected to drive the market in the forecast period.

Key Market Trends

Myocardial Infarction Segment is Expected to Show Better Growth in the Forecast Years

Based on the application, it is segmented into Congestive Heart Failure, Acute Coronary Syndrome, Myocardial Infarction, Atherosclerosis, and Others. The key factor contributing to the growth of the segment is the rising number of cardiovascular disorders. According to the American College of Cardiology, approximately every 40 seconds, an American will have a myocardial infarction. The average age of first myocardial infarction is 65.6 years old for men and 72.0 years old for women. Many companies are focusing on developing breakthrough products for the treatment of cardiovascular disease. Hence, with the rising government initiatives and wide applications of biomarkers in cardiac diagnostics, the market is expected to grow over the forecast period.

North America Dominates the Cardiac Biomarkers Market

The cardiac biomarkers market holds the largest share in North America region. According to the American Heart Association around 2,300 Americans die of cardiovascular disease each day. The cardiac markers help in monitoring the prognosis of certain condition with greater accuracy and providing the most effective treatment to the patients Hence, with the rising concerns regarding cardiovascular disorders and increasing spending on R&D of novel biomarkers, the market is expected to grow over the forecast period.

Competitive Landscape

The global players in the cardiac biomarkers market are – Abbott Laboratories, Becton, Dickinson and Company, BioMérieux, Bio-Rad Laboratories, Inc., Danaher Corporation, F. Hoffmann-La Roche AG, Randox Laboratories, Siemens Healthineers, and Thermo Fisher Scientific.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support
レポート目次

1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Cardiovascular Diseases
4.2.2 Technological Advancements in the Cardiac Biomarkers
4.2.3 Growing Funding From Public and Private Organizations for R&D
4.3 Market Restraints
4.3.1 Stringent Regulatory Framework
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 By Type
5.1.1 Creatine Kinase
5.1.2 Troponins
5.1.3 Myoglobin
5.1.4 Ischemia Modified Albumin
5.1.5 Others
5.2 By Application
5.2.1 Congestive Heart Failure
5.2.2 Acute Coronary Syndrome
5.2.3 Myocardial Infarction
5.2.4 Atherosclerosis
5.2.5 Others
5.3 By Location Of Testing
5.3.1 Point of Care Testing
5.3.2 Laboratory Testing
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle-East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle-East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Abbott Laboratories
6.1.2 Becton, Dickinson and Company
6.1.3 BioMerieux
6.1.4 Bio-Rad Laboratories, Inc.
6.1.5 Danaher Corporation
6.1.6 F. Hoffmann-La Roche AG
6.1.7 Randox Laboratories
6.1.8 Siemens Healthineers
6.1.9 Thermo Fisher Scientific

7 MARKET OPPORTUNITIES AND FUTURE TRENDS